Jake Bauer Sells 5,000 Shares of Myokardia Inc (MYOK) Stock
Myokardia Inc (NASDAQ:MYOK) insider Jake Bauer sold 5,000 shares of the stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the transaction, the insider now owns 56,777 shares of the company’s stock, valued at $2,554,965. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Jake Bauer also recently made the following trade(s):
- On Tuesday, January 2nd, Jake Bauer sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $42.89, for a total transaction of $214,450.00.
Shares of Myokardia Inc (MYOK) traded up $0.25 during trading hours on Thursday, reaching $48.70. 55,447 shares of the company traded hands, compared to its average volume of 631,843. Myokardia Inc has a twelve month low of $10.55 and a twelve month high of $49.55. The firm has a market cap of $1,750.00 and a P/E ratio of -65.81.
Myokardia (NASDAQ:MYOK) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.42). Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The business had revenue of $5.63 million during the quarter, compared to the consensus estimate of $6.10 million. During the same period last year, the business posted ($0.35) EPS. Myokardia’s revenue was up 58.6% on a year-over-year basis. research analysts expect that Myokardia Inc will post -1.62 EPS for the current year.
MYOK has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Myokardia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Credit Suisse Group reiterated an “outperform” rating and issued a $55.00 target price (up from $45.00) on shares of Myokardia in a research note on Tuesday, September 19th. TheStreet downgraded shares of Myokardia from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. JPMorgan Chase & Co. initiated coverage on shares of Myokardia in a research note on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 target price for the company. Finally, BidaskClub upgraded shares of Myokardia from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $54.83.
A number of institutional investors have recently added to or reduced their stakes in MYOK. Schwab Charles Investment Management Inc. raised its holdings in Myokardia by 31.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 57,546 shares of the biotechnology company’s stock valued at $754,000 after acquiring an additional 13,866 shares during the period. Rhumbline Advisers raised its holdings in Myokardia by 45.4% in the 2nd quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock valued at $242,000 after acquiring an additional 5,773 shares during the period. State of Wisconsin Investment Board bought a new position in Myokardia in the 2nd quarter valued at about $157,000. Bank of New York Mellon Corp raised its holdings in Myokardia by 11.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 63,208 shares of the biotechnology company’s stock valued at $828,000 after acquiring an additional 6,603 shares during the period. Finally, Swiss National Bank raised its holdings in Myokardia by 25.7% in the 2nd quarter. Swiss National Bank now owns 31,790 shares of the biotechnology company’s stock valued at $416,000 after acquiring an additional 6,500 shares during the period. 63.61% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Jake Bauer Sells 5,000 Shares of Myokardia Inc (MYOK) Stock” was published by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/jake-bauer-sells-5000-shares-of-myokardia-inc-myok-stock-2/1802998.html.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with Analyst Ratings Network's FREE daily email newsletter.